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Rationale: An effective new tuberculosis (TB) vaccine regimen must
be safe in individuals with latent TB infection (LTBI) and is a priority
for global health care.
Objectives: To evaluate the safety and immunogenicity of a leading
new TB vaccine, recombinant Modified Vaccinia Ankara expressing
Antigen 85A (MVA85A) in individuals with LTBI.
Methods: Anopen-label, phase I trial ofMVA85Awasperformed in12
subjects with LTBI recruited from TB contact clinics in Oxford and
London or by poster advertisements in Oxford hospitals. Patients
were assessed clinically and had blood samples drawn for immuno-
logical analysis over a 52-week period after vaccination with
MVA85A. Thoracic computed tomography scans were performed
at baseline and at 10weeks after vaccination. Safety ofMVA85Awas
assessed by clinical, radiological, and inflammatory markers. The
immunogenicity of MVA85A was assessed by IFNg and IL-2 ELISpot
assays and FACS.
Measurements and Main Results: MVA85A was safe in subjects with
LTBI, with comparable adverse events to previous trials of MVA85A.
Therewereno clinically significant changes in inflammatorymarkers
or thoracic computed tomography scans after vaccination.MVA85A
induced a strong antigen-specific IFN-g and IL-2 response that was
durable for 52 weeks. The magnitude of IFN-g response was
comparable to previous trials of MVA85A in bacillus Calmette-
Gue´rin–vaccinated individuals. Antigen 85A–specific polyfunctional
CD41 T cells were detectable prior to vaccination with statistically
significant increases in cell numbers after vaccination.
Conclusions: MVA85A is safe and highly immunogenic in individuals
with LTBI. These results will facilitate further trials in TB-endemic
areas.
Clinical trial registered with www.clinicaltrials.gov (NCT00456183).
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One-third of the world’s population is estimated to be infected
with Mycobacterium tuberculosis, on the basis of tuberculin skin
testing (TST) (1). In individuals with latent tuberculous infection
(LTBI), mycobacteria are viable but in a poorly understood state
of dormancy (2, 3). They do not cause disease but have the
capacity to do so at a later time point. Reactivation of these
mycobacteria gives infected immunocompetent individuals a 5 to
10% lifetime risk of developing postprimary disease. This huge
reservoir for tuberculosis (TB) disease is an essential group to
consider when developing new vaccines against M. tuberculosis,
because latent infection may alter the adverse event profile or
therapeutic efficacy of vaccination.
An improved vaccine regimen that is more effective than the
currently available bacillus Calmette-Gue´rin (BCG) would have
a major impact on the global TB burden. It is conceivable that an
effective vaccine could intervene before or after exposure to
M. tuberculosis. The aim of a postexposure vaccine, for use in
individuals with LTBI, would be to reduce the probability of
developing TB disease in the future. Such a vaccine might
potentially work by sterilizing bacteria that are residing in
a dormant state, by preventing reactivation, and/or by reducing
the chance of reinfection by exogenous M. tuberculosis. This is
relevant because 19% of individuals are simultaneously infected
with multiple strains in areas of high TB endemicity (4). Myco-
bacteria change their transcription patterns during different
clinical conditions (2, 5, 6), but it remains unclear whether
vaccines designed primarily as preexposure vaccines could be
effective in the infected or active disease setting. The majority of
TB vaccine research to date has been in the development of
vaccines designed primarily as preexposure vaccines. MVA85A
was the first subunit vaccine of this type to enter phase I clinical
trials in 2002 (7).
To date, trials with MVA85A have been in BCG-naive and
BCG-vaccinated subjects. There have been safety concerns
within the field that potent new TB vaccines may induce
mycobacteria-specific immunopathology in subjects with LTBI.
Furthermore, few vaccines have been effective in the presence of
chronic preexposure to the vaccine antigen. This is believed to be
the result of poorly defined immunoregulatory mechanisms and
greatly complicates the challenge of therapeutic vaccination.
Latent infection withM. tuberculosis is one of the most prevalent
bacterial infections in humans and could potentially tolerize to
subsequent vaccine antigen administration. These concerns have
influenced case selection for early clinical trials of new TB
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
MVA85A is the first new vaccine to be evaluated in
Mycobacterium tuberculosis latently infected subjects.
What This Study Adds to the Field
MVA85A is safe and highly immunogenic in individuals
with LTBI. These results will facilitate further trials in
TB-endemic areas.
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vaccines. However, in real clinical practice vaccination of subjects
with LTBI will be unavoidable (and perhaps desirable). There-
fore, the aim of this open-labeled phase I clinical trial was to
evaluate the safety and immunogenicity of MVA85A in subjects
with LTBI.
METHODS
Participants
This study was conducted according to a protocol approved by the
Oxford Research Ethics Committee (OxREC A; 04/Q1604/61), Clin-
icalTrials.gov ID NCT00456183. Participants were recruited for this trial
from TB contact clinics in the Oxford Radcliffe Hospital (ORH)
National Health Service (NHS) Trust and the North West London
Hospitals Trust and by poster campaign within hospitals of the ORH
NHS Trust. This called for individuals who knew that they had been
exposed to TB or who had been told historically that they had LTBI.
Written informed consent was obtained from all subjects prior to
enrolment in the trial. To be eligible for screening participants needed
to be in good health with no clinical evidence of TB disease, be between
the ages of 18 and 50 years, have a Heaf test between grade II and IV, and
have a normal chest radiograph. Latent infection in this clinical trial was
defined using an in-house ex vivo IFN-gELISpot assay using the two M.
tuberculosis–specific antigens, early-secreted antigenic target 6 kD pro-
tein (ESAT-6) and culture filtrate protein 10 (CFP-10), used in the
commercially available diagnostic tests (8, 9). To be enrolled into the
trial, participants needed to produce at least 50 spot-forming cells (SFC)/
million peripheral blood mononuclear cells (PBMCs) for any of six pools
of either ESAT-6 or CFP-10 peptides on the in-house ex vivo IFN-g
ELISpot assay. This assay has a sensitivity of 15 SFC/million, so at 50
SFC/million we were ensuring that individuals recruited were well above
the sensitivity of the assay. Participants were required to be seronegative
for HIV, hepatitis B virus, and hepatitis C virus, and to have normal full
blood count, renal, and liver function tests. Females entering the study
were required to have a negative pregnancy test prior to entry, no plans
for conception during the year of the study, and plans for secure
contraception during this period.
Vaccine
The construction of the MVA85A vaccine has previously been described
(10). Clinical grade MVA was produced under Good Manufacturing
Practice standard by IDT Biologika GmbH (Dessau, Germany). Approval
for the study was granted by the Medicines and Healthcare products
Regulatory Agency (MHRA), UK, initially under a Doctors and Dentists
Exemption Certificate (DDX; MF8000/12078). This was subsequently
converted to a Clinical Trial Authorization (CTA; 21,584/0014/001) after
the instigation of the European Union Clinical Trials Directive in May
2004.
Enrollment and Follow-up
Participants enrolled in the study were vaccinated with 5 3 107 plaque-
forming units administered intradermally. All volunteers were followed
up regularly for 12 months with blood samples being taken for in-
flammatory markers (blood erythrocyte sedimentation rate [ESR] and
C-reactive protein [CRP]), and immunological assays. Routine hema-
tology and biochemistry assays were performed at Weeks 1 and 12 after
vaccination. A diary card was completed by all volunteers recording local
and systemic adverse events and body temperature for Days 1 to 7
postvaccination. Throughout the study the local policy for the manage-
ment of LTBI was followed, with agreement that chemoprophylaxis
could be delayed for a year (the duration of the study) for subjects with
LTBI who were either new arrivals in the UK or contacts of non-
pulmonary TB cases. Contacts of recent smear-positive cases of pulmo-
nary TB were excluded because it was believed that such individuals
needed immediate chemoprophylaxis.
High-Resolution Computerized Tomographic Scan
A high-resolution computerized tomographic scan (HRCT) of the
thorax was performed prior to vaccination and at 10 weeks postvaccina-
tion using a GE Lightspeed computed tomography (CT) scanner (GE
Healthcare, Chalfont St. Giles, UK) and a protocol consisting of five
1-mm HRCT sections through the upper lobes. Volumetric CT, through
the upper lobes with 1.25-mm contiguous sections, was performed in the
subject who developed pulmonary nodules and this subject was sub-
sequently followed up with a low-dose volumetric CT. All scans were
reported by one senior respiratory radiology consultant (F.V.G.) who
was not blinded to the study.
Immunological Assays
ELISpot assays. The ex vivo IFN-g and IL-2 ELISpot assays were
performed on blood taken at screening and at Weeks 1, 4, 12, 24, and
52 postvaccination using fresh PBMCs. Tuberculin PPD (20mg/ml, SSI),
recombinant antigen 85A (Ag85A)(10 mg/ml, University of Leiden),
seven pools of 9–10 peptides of Ag85A (ABC peptides, Imperial College
London), three pools of 5–6 peptides of ESAT-6 (Peptide Protein
Research, Hampshire, UK) and three pools of six peptides of CFP-10
(Peptide Protein Research) were used as stimulants for the IFN-g assays.
Stimulation was with Ag85A and the seven pools of 9–10 peptides of
Ag85A for the IL-2 assay. All of the peptides used were 15mers
overlapping by 10 amino acids, being used at a final concentration of
10 mg/ml in each well. Briefly, for the IFN-g assay, 300,000 PBMCs were
plated per well in 100 ml R10 (RPMI plus 10% fetal calf serum [FCS],
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin sulfate,
and 1 mM sodium pyruvate) directly onto the ELISpot plate (MAIP
S4510 Millipore, Billerica, MA) in the presence of antigen and the plate
was incubated for 18 hours. Streptokinase (250 U/ml), streptodornase
(12.5 U/ml) and phytohemagglutinin (10mg/ml) were used in all assays as
positive controls and R10 and PBMCs were used as a negative control.
The IL-2 ELISpot was performed according to the manufacturers
instructions (R&D, Abingdon, UK), with the following minor method-
ological differences: R10 was used for blocking instead of the specified
blocking buffer, 50 ml of diluted capture and detection antibodies were
used instead of 100 ml, and detection antibody was incubated for 4 hours
instead of overnight. For the IL-2 ELISpot assay, 300,000 PBMCs were
plated per well in 100 ml R10 directly onto the ELISpot plate.
Assays were performed in duplicate. The ELISpot data were
analyzed by subtracting the mean number of SFCs produced from the
negative control wells from the mean count from wells with antigens. A
well was considered positive if the count was at least twice that in the
negative control wells and at least 5 SFC more than the negative control
wells. The upper limit of quantification was taken as 500 SFC per well.
For the peptide pool wells, the results were summed across all peptide
pools for each time point. This potentially resulted in duplicate counting
of T cells that responded to any of the 10mer overlap regions, because any
10mer occurred in two pools with adjacent peptides, but allowed direct
comparison with immunogenicity data from previous trials (7, 11).
Intracellular cytokine staining assay. Flow cytometric analysis of
Ag85A-specific T-cell responses was performed at screening, and Weeks
1, 4, and 24 after vaccination. Thawed PBMCs were rested overnight in
R10 supplemented with 10 U/ml DNase I (DNase I; Ambion, Applied
Biosystems, Cheshire, UK). The following morning PBMCs were
adjusted to 1 3 106 cells/ml in R10 in the presence of 1 mg/ml aCD28,
1mg/ml aCD49d (both from BD Biosciences, Oxford, UK) and 10mg/ml
brefeldin A (Sigma-Aldrich, Dorset, UK). PBMCs were incubated at
378C with 5% CO2 for 6 hours with 2mg/ml antigen 85A complete peptide
pool (66 15-mer peptides overlapping by 10 amino acids; 2 mg/ml final
concentration for each individual peptide). Unstimulated PBMCs were
used to assess nonspecific cytokine production. After stimulation,
PBMCs were washed in FACS buffer (PBS containing 1% FCS and
0.1% sodium azide [Sigma-Aldrich]), then stained with the amine
reactive LIVE/DEAD fixable violet dead cell stain kit (Molecular
Probes, Invitrogen, Paisley, UK) (12) and fluorochrome conjugated,
monoclonal antibodies (mAbs) against CD4 (allophycocyanin [APC],
Ebioscience, London, UK) and CD14 (Pacific Blue; Caltag, Invitrogen).
Subsequently, PBMCs were washed, permeabilized (Cytofix/cytoperm
kit; BD Pharmingen, Oxford, UK) according to the manufacturer’s
instructions, stained for CD3 (phycoerythrin [PE]-cyanine 5 [Cy5];
Ebioscience), CD8 (APC-Alexafluor 750; Molecular Probes, Invitrogen)
and cytokines IFN-g (fluorescein isothiocyanate; Ebioscience), IL-2 (PE;
Ebioscience), and TNF-a (PE-cyanine 7, BD Biosciences) washed and
fixed in 1% paraformaldehyde. Cells were analyzed using a CyAn ADP
cytometer (Dako Cytomation, Glostrup, Denmark). Antigen-specific
cytokine responses and functional profiles were assessed and performed
as previously described using FlowJo version 8.4 (Tree Star Inc., Ashland,
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OR), Pestle version 1.5 and Simplified Presentation of Incredibly Complex
Evaluations (SPICE) version 3.1, both provided by Mario Roederer,
Vaccine Research Center, National Institute of Allergy and Infectious
Diseases, National Institutes of Health (13).
Statistical Analysis
Vaccine-induced responses at peak (1 wk) and plateau (6 or 12 mo) were
compared with baseline responses using the Wilcoxon signed rank test for
matched pairs, Stata Statistical Software, Release 9.0. 2005 (Stata Corpo-
ration, College Station, TX). Comparisons between vaccine-induced
responses in this trial and those from previous trials of MVA85A were
made using the Mann-Whitney test, also using Stata.
Role of the Funding Source
This trial was funded by the Wellcome Trust and the sponsor was the
University of Oxford. The funder had no role in the design of this study or
in the analysis of the data.
RESULTS
Demographics
Twenty five individuals were screened between September 2004
and November 2005 to provide 12 participants (see consort
diagram in Figure 1). Twelve individuals were excluded because
they did not fulfill the ESAT-6/CFP-10 ELISpot criteria. One
subject was excluded because of abnormal liver function tests.
Five other people were booked for screening but failed to attend.
The demographics of the 12 participants who entered the trial
are shown in Table 1. Nine participants were recruited from TB
contact clinics with seven being from countries of high TB
endemicity. Three were being screened because they were new
arrivals in the UK, and three had had recent contact with a TB
case. One participant from a country of high TB endemicity and
two others were in the TB clinic at the request of their NHS
occupational health departments. The three participants who
responded to the poster advertisements had all been told
historically that they had LTBI but had never received any
treatment.
Participants had a range of Heaf test results but there was no
correlation between Heaf grade and magnitude of IFN-g
responses to either ESAT-6 or CFP-10 or to the summed
ESAT-6 and CFP-10 responses determined by the ELISpot assay
(data not shown). All volunteers reached the entry criteria for this
study on the basis of CFP-10 responses, whereas only 8 out of 12 of
these subjects fulfilled entry criteria from ESAT-6 responses
alone.
Two of the three subjects with a grade IV Heaf test had not
been vaccinated with BCG, and both of these subjects were white.
The two subjects with hilar calcification on baseline thoracic CT
scanning had grade IV Heaf tests. The participants with grade IV
Heaf results were vaccinated toward the end of the study after
participants with grade II and III Heaf tests had been safely
vaccinated. This was based on a prior assumption that higher
Figure 1. The Consort E-Flowchart, August 2005. Con-
sort diagram for study.
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Heaf grades related to higher bacterial loads and to potentially
higher risks of developing adverse events due to immunopathology.
Local Adverse Events
Local reactions relating to the MVA vaccine vector occur during
the first week after vaccination and have been reported pre-
viously (7, 11). The dose of MVA85A used in this trial is the same
as that used in the previous trials of MVA85A, 5 3 107 plaque-
forming units (7). The local adverse event profile recorded in
diary cards is comparable between all of the trials of MVA85A
(Table 2). It is also worth noting that no volunteer complained of
any increased reactogenicity at the TST site nor was any noticed
by the trial clinicians.
Systemic Adverse Events
Systemic symptoms also occurred during the first week of
vaccination and were recorded in the diary cards (see Table 2).
Documented fever of more than 37.58C was the only objective
sign in the previous studies and occurred in 2% of subjects. This
did not occur in any subjects in this trial. All of the other
symptoms were subjective, with similar percentages of subjects
experiencing them in this trial compared with previous trials.
There was no suggestion from any of the symptoms or signs that
there had been induction of any mycobacteria-specific immuno-
pathology.
Inflammatory markers were monitored throughout the study.
There were no clinically significant increases in ESR and CRP
measures for 11 out of 12 participants throughout the study. One
subject fractured his ankle 2 weeks after vaccination and de-
veloped an increase in his CRP after this fracture from 8 to
160 mg/L and in ESR from 5 to 28 mm/hour, which persisted until
Week 4. This response was considered to be unrelated to
vaccination. There were no significantly abnormal biochemistry
or hematology blood test results in any subject during the course
of the studies.
There were no changes in the HRCT scans at baseline and 10
weeks postvaccination, except in one participant. A 5-mm
pulmonary nodule was visualized in the right upper lobe on
the 10-week scan, which had not been visualized on the original
prevaccination scan. However, the small volume calcified hilar
lymphadenopathy that had been detected in the same subject at
screening remained unchanged on the 10-week scan. A further
scan, performed at 14 weeks, demonstrated complete resolution
of this nodule. The patient was asymptomatic throughout this
period.
Immunogenicity of Vaccine Determined by IFN-g
and IL-2 ELISpot
At 1 week postvaccination, the frequency of IFN-g–secreting T
cells responding to Ag85A increased by a median of 933 SFC/
million compared with screening (95% confidence interval [CI],
567–1,360; P 5 0.002). There remained an increased frequency
of Ag85A-specific T cells throughout the trial follow-up. At 52
weeks this response remained significantly higher than baseline
(median difference, 275; 95% CI, 103–437; P 5 0.006) (Figure
2a). The T-cell responses to the Ag85A peptide pools followed
a similar pattern, with a median increase above baseline of 3,637
SFC/million (1,419–5,831; P5 0.002) at Week 1 and of 495 SFC/
million (72–1,102; P 5 0.017) at 52 weeks (Figure 2B). The
kinetics of this Ag85A-specific T-cell response are very similar
to previous studies of MVA85A and consistent with under-
standing of T-cell expansion and contraction to memory phase
(14).
The median PPD response before vaccination was 959 (range
240–1,650) SFC/million PBMCs, which was significantly higher
than that seen in the previous trial of MVA85A in BCG-
vaccinated subjects where the baseline PPD response was 60
(0–465) (median difference,2853; 95% CI,21,242 to2428; P,
0.0001) (7). As a consistent number of PBMCs were added to each
well in the ELISpot assay across these trials, this higher baseline
response to PPD meant we were unable to detect a significant
increase in number of PPD-specific T cells after vaccination in this
population at Week 1 (median difference, 135; 95% CI, 215 to
718; P5 0.07) or Week 52 (median difference, 29; 95% CI,2209
to 506; P 5 0.39) (7, 11).
The immunogenicity of MVA85A in this trial in LTBI subjects
was compared with the immunogenicity of MVA85A in previous
trials in BCG-vaccinated subjects (Figure 3). The magnitude of T-
cell response to Ag85A prevaccination was significantly higher in
those with LTBI compared with those just vaccinated with BCG
at screening, with median difference of 96.3 to rAg85A (95%
CI, 47–186; P 5 0.003) and of 91 to summed peptide pools
(11–251;P5 0.006). However, there was no significant difference
in the magnitude of T-cell response to Ag85A or to the 85A
TABLE 1. DEMOGRAPHICS AND SCREENING RESULTS
OF TRIAL PARTICIPANTS
Sex Male 10 (83.3%)
Female 2 (16.7%)
Median age (range) 30.5 (20–49)
Country of birth India 5 (41.7%)
East Africa 2 (16.7%)
England 2 (16.7%)
West Africa 2 (16.7%)
Ireland 1 (8.3%)
BCG vaccinates Yes 10 (83.3%)
No 2 (16.7%)
Heaf result Grade II 7 (58.3%)
Grade III 2 (16.7%)
Grade IV 3 (25%)
Median ESAT-6 (range) 148 (3–1,773)
Median CFP-10 (range) 459 (77–2,037)
Baseline computed
tomography scans
Normal 10 (83.3%)
Abnormal (hilar calcification) 2 (16.7%)
Definition of abbreviations: BCG 5 bacillus Calmette-Gue´rin; CFP 5 culture
filtrate protein; ESAT 5 early-secreted antigenic target
TABLE 2. COMPARISON OF ADVERSE EVENTS BETWEEN
TRIALS OF MVA85A IN SUBJECTS WITH AND WITHOUT
LATENT TUBERCULOUS INFECTION
Latency Trial Previous Trials of MVA85A*
(n 5 12) (n 5 41)
Local adverse events
Redness 11 (92%) 41 (100%)
Pruritus 8 (67%) 35 (85%)
Pain 6 (50%) 39 (95%)
Induration 11 (92%) 41 (100%)
Systemic adverse events
Fever 0 (0%) 5 (12%)
Flu-like 4 (33%) 17 (41%)
Arthralgia 1 (8%) 12 (29%)
Headache 7 (58%) 17 (41%)
Myalgia 5 (42%) 20 (49%)
Nausea 0 (0%) 6 (15%)
Tired 7 (58%) Not recorded
Vasovagal syncope 0 (0%) 1 (2%)
Values are n (%).
* See References 7 and 11.
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peptide pools in those infected with TB compared with those just
vaccinated with BCG at either 1 week (median difference, 10;
95% CI,2861 to 228;P5 0.56 for Ag85A and median difference,
2351; 95% CI, 23,077 to 1,623; P 5 0.66 for Ag85A pools) or
52 weeks (median difference, 2129; 95% CI, 2416 to 164; P 5
0.57 for Ag85A and median difference, 0; 95% CI, 2607 to 414;
P5 1.00 for Ag85A pools) postvaccination. Ten of the 12 subjects
in this LTBI trial had been vaccinated with BCG during child-
hood. The immunogenicity of MVA85A in the 2 subjects who had
not received BCG was not significantly different from the median
of the BCG-vaccinated subjects in this trial, suggesting that
M. tuberculosis infection can act as a prime for subsequent
MVA85A boosting in a similar way to BCG (data not shown).
The kinetics of induction of IL-2–producing T cells in response
to Ag85A and 85A peptide pools follows a very similar pattern to
that of the IFN-g–producing T cells (see Figure 2, Figure 4). At
Week 1 there was a significant increase from baseline in both IL-
2–producing T cells in response to Ag85A (median difference,
877; 95% CI, 430–1,320; P 5 0.007) and the summed Ag85A
peptide pools (median difference, 2,566; 95% CI, 1,236–3,783;
P5 0.007), when compared with baseline responses. The Ag85A
response remained significantly above baseline at 1 year after
vaccination (median difference, 247; 95% CI, 40–460;P5 0.018).
The summed peptide pool response just failed to remain signif-
Figure 2. MVA85A vaccination expands antigen 85A-specific IFN-g–
secreting T cells. Median IFN-g ELISpot responses to (A) Ag85A, and the
summed responses to (B) Ag85A peptide pools, for n 5 12 for all time
points except Week 4, where n 5 11 due to subject unavailability. The
responses to each antigen at 1 week, 24 weeks, and 52 weeks after
vaccination were compared with Week 0 using the Mann-Whitney test.
Figure 3. MVA85A vaccination is as effective at expanding antigen
85A-specific IFN-g–secreting T cells in subjects with latent tuberculosis
infection (LTBI) as in subjects who have been bacillus Calmette-Gue´rin
(BCG) vaccinated, despite higher baseline antigen 85A–specific
responses. Median IFN-g ELISPOT responses to Ag85A and summed
peptide pools in this trial (n 5 12) compared with a previous trial of
MVA85A in subjects vaccinated with BCG at (A) screening (n 5 22), (B)
1 week (n 5 17), and (C) 52 weeks (n 5 9) after vaccination with
MVA85A. The responses to each antigen at each time point for each
trial were compared using the Mann-Whitney test.
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icantly above baseline at 1 year (median difference, 461; 95% CI,
23 to 1,191; P 5 0.051).
MVA85A Vaccination Expands Multifunctional
CD41 T-cell Populations
Flow cytometric analysis revealed antigen 85A–specific CD41 T-
cell populations, which were able to produce the cytokines IFN-g,
IL-2, and TNF-a prior to vaccination. This is markedly different
from the responses observed in non–M. tuberculosis infected,
BCG-vaccinated subjects, where at baseline there were lower
numbers of Ag85A-specific CD41 T cells and those detected
produced single cytokines only (13) (Figure 5).
Vaccination with MVA85A induced significant changes in the
magnitude of IFN-g1IL-21TNF-a1 (31) and the IFN-g1TNF-
a1 (21) Ag85A-specific CD41 T cell response at Week 1 (see
Figure 5; P 5 0.006, P 5 0.007, respectively). The functional
composition of the Ag85A-specific response was also altered
after vaccination with MVA85A. At 1 week more than 50% of the
responding CD41T cells were producing IFN-g1IL-21TNF-a1
(31). At 24 weeks after MVA85A a larger proportion of the
Ag85A-specific response was composed of IFN-g1TNF-a1
(21)–responding CD41 T cells than prior to MVA85A vaccina-
tion. No Ag85A-specific CD81 T-cell responses were detected
after vaccination with MVA85A, determined by flow cytometry,
which is similar to the non–M. tuberculosis–infected cohort (13).
A comparison of the levels of IFN-g and IL-2 measured by
ELISpot and ICS prior to and at the 1-, 4-, and 24-week time
points revealed a close correlation between the two assays: IFN-g
P , 0.0000, Spearman’s r 5 0.85 with 41 observations and IL-2
P 5 0.0000, Spearman’s r 5 0.84 with 33 observations (data not
shown).
Effect of Vaccination on Immune Response to Other
Mycobacterial Antigens
There are no changes after vaccination in the median frequency
of T cells responding to the early secreted mycobacterial antigens,
ESAT-6 at Week 1 (median difference,253; 95% CI,2137 to 34;
P5 0.39) or Week 52 (median difference,213; 95% CI,2115 to
386; P 5 0.58) and CFP-10 at Week 1 (median difference, 224;
95% CI, 2214 to 237; P 5 0.53) or Week 52 (median difference,
193; 95% CI,220 to 480;P5 0.07) (Figure 6). This contrasts with
the increased T-cell frequency seen in response to Ag85A, the
gene that is encoded within the MVA85A vaccine, over the time
course. Even when responses were investigated on an individual
level, there were no statistically significant changes in responses
to any of these antigens when normalized for frequency of
response to streptokinase-streptodornase (data not shown).
DISCUSSION
The two main findings from this phase I clinical trial are (1)
MVA85A is safe in healthy subjects latently infected with
M. tuberculosis, and (2) MVA85A is highly immunogenic in
this population.
Subjects were defined as having LTBI for this trial using an in-
house ex vivo IFN-g ELISpot assay to ESAT-6 and CFP-10. A
modified version of this assay and a whole blood IFN-g ELISA
using the same antigens have been validated and commercialized
and are known as the T-SPOT.TB test (Oxford Immunotec,
Oxford, UK) and the QuantiFERON-TB Gold (QFT-G) assay,
respectively. They are both more specific than the TST and are
starting to play a role in TB diagnosis (15). The enhanced
specificity of these assays relates to the fact that the antigens
ESAT-6 and CFP-10 are not present in BCG or most environ-
mental mycobacteria. The Centers for Disease Control and
Prevention (CDC) in the United States now recommend that
the TST be replaced by QFT-G for all indications, including
screening of contacts, immigrants, and health care workers (8). In
the United Kingdom, the National Institute for Health and
Clinical Excellence (NICE) recommends continuing with the
TST but considering the use of either of the more specific assays in
those who are TST-positive or in those in whom the TST may be
unreliable (9).
The local and systemic adverse event profile seen in this trial
was very similar to that seen in previous trials in naive and BCG-
vaccinated subjects. Specifically, we did not see any mycobacteria-
specific immunopathology after vaccination, the so-called ‘‘Koch
phenomenon.’’ In the 1890s, after preliminary experiments in
guinea pigs, Robert Koch administered culture filtrate tubercu-
losis proteins to patients with active TB in the hope that it would
be therapeutic. Unfortunately, this triggered a potent immuno-
logical response inducing tissue necrosis in some subjects that was
sometimes lethal (16). Murine models have suggested that this
Koch phenomenon is more likely to occur in animals with a higher
mycobacterial load, because immunopathology developed when
DNA vaccination was given to mice with active TB but not to
those with latent TB (17). Due to the concern about the possibility
of inducing a Koch phenomenon, clinical trials of MVA85A were
initially performed in those as mycobacterially naive as possible
Figure 4. MVA85A vaccination expands antigen 85A–specific IL-2–
secreting T cells. Median IL-2 ELISpot responses to (A) Ag 85A and the
summed responses to (B) Ag85A peptide pools for n 5 10 for all time
points except Week 52, where n 5 7 due to reagent unavailability. The
responses to each antigen at 1 week, 24 weeks, and 52 weeks after
vaccination were compared with Week 0 using the Mann-Whitney test.
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(PPD negative on skin test, BCG naive), progressing thereafter to
subjects vaccinated with BCG (18). MVA85A has been shown to
be well tolerated in these populations and highly immunogenic in
the context of previous BCG. This trial now extends these
reassuring results by showing that vaccination is safe and highly
immunogenic in individuals with established LTBI, allowing
progression to larger phase II trials in parts of the world where
there is a very high prevalence of latent infection and also the
greatest need for improved vaccines (7).
It is difficult to be certain whether the transient development
of a single pulmonary nodule in one subject in the interval
between screening and repeat scanning at 10 weeks was vaccine
related. This subject was 29 years of age with a 13 pack-year
history of smoking (20 cigarettes per day for 13 yr) and a grade IV
Heaf at screening. His nodule may have developed at any stage
prior to his 10-week scan, and had fully resolved by 14 weeks. He
remained asymptomatic throughout the trial period. It is also
possible that the nodule was present prevaccination and was not
visualized on the baseline HRCT screening scan, because this was
a limited examination of five CT slices (to minimize ionizing
radiation exposure). Noncalcified pulmonary nodules are com-
mon and frequently identified on thoracic HRCT scan in the
absence of any specific disease (19). Such nodules are detected in
5 to 66% of individuals who smoke (as our trial participant did)
(20–26). Resolution or reduction in size of these nodules is also
well recognized, with nodules of less than or equal to 5 mm being
the most likely to resolve (20, 27). Possible diagnoses that have
been proposed for resolving nodules include focal inflammatory
lesions, mucoid impaction in small bronchi, or intermittent
enlargement of benign intrapulmonary lymph nodes.
This trial has demonstrated that MVA85A is equally immu-
nogenic in individuals with LTBI as it is in individuals uninfected
with M. tuberculosis but vaccinated with BCG. Vaccine-induced
immune responses persisted with significantly more Ag85A pro-
tein and peptide pool–specific IFN-g–secreting T cells present at
1 year after vaccination compared with prevaccination. Interest-
ingly, the kinetic and pattern of IL-2 secretion on ELISpot closely
mirrored the IFN-g secretion and this response was equally
durable. Although it is known that IFN-g is essential for pro-
tection, it is increasingly being recognized that alone it is not
a good correlate of protection (28–32). Other cytokines are
clearly also important in protective immunity against TB. IL-2
Figure 5. MVA85A vaccination
expands multifunctional CD41
T-cell populations. (A) The
group functional profiles of
Ag85A-specific CD41 T cells
throughout the vaccination
time course are shown (n 5
10 for Week 1, 11 for Week 4,
and 8 for Week 24). Responding
cells (able to produce any of the
following cytokines: IFN-g, IL-2,
or TNF-a) were grouped and
color coded according to the
number of cytokines produced.
(B) The absolute Ag85A-specific
CD41 T-cell responses are
shown for each of the possible
functional species (along the x
axis) throughout the vaccina-
tion time course. Individual
data points are shown with
median line, interquartile
range boxes, and minimum/
maximum whiskers. Signifi-
cant (P , 0.05) increases
above baseline levels are
shown (Wilcoxon signed rank
test for matched pairs).
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is known to be critically important in growth and stimulation of T
cells, B cells, and NK cells (33, 34) and is important in the
establishment of T-cell memory (35). In addition to effector
T-cell responses, it may be important to monitor Th-2 and reg-
ulatory T-cell responses, because these may be important in pro-
tective immunity and in vaccine efficacy (36).
Induction of a potent antigen-specific T-cell response is likely
to be paramount for an effective TB vaccine and there is evidence
from a number of systems of the importance of polyfunctional T
cells in protective immunity against intracellular pathogens (37,
38). Using polychromatic flow cytometry to investigate the func-
tionality of Ag85A-specific CD41T cells induced by MVA85A in
this trial revealed similarities and differences to that previously
reported for a BCG-vaccinated cohort (13). The functional
profile of the cells at baseline was markedly different in the LTBI
group compared with the BCG-vaccinated group. At baseline the
profile was considerably more polyfunctional than in the BCG-
vaccinated group where only monofunctional cells were identi-
fied. This is supportive evidence for this population being
immunologically different from the non-LTBI population and
the fact that these cells are present may suggest that they are an
important T-cell subset in natural host immunity against TB
disease. As in the previous trial, there was a significant increase in
magnitude of 31 cells compared with baseline after vaccination
with MVA85A. It would be interesting to serially investigate the
persistence of the polyfunctional T cells in individuals with LTBI
to examine whether these 31CD41T-cell populations decline in
frequency in those individuals who go on to develop active TB
disease.
It will not be possible to ascertain whether the immune
responses induced by MVA85A are of clinical significance until
an efficacy trial is completed. Performing extensive immunolog-
ical analysis in subjects vaccinated in early studies, such as this
phase 1 trial, is important because it will eventually facilitate the
identification and understanding of protective correlates of
immunity against TB.
In this trial no change was detected in either the median or
individual frequency of T-cell responses to ESAT-6 or CFP-10
during the year of follow-up after vaccination. Although there is
some evidence from animal studies to suggest that the strength of
reactivity to these antigens relates to bacterial load and pathology
(39, 40), data are more conflicting from human studies. Correla-
tions between T-cell frequency to ESAT-6 and CFP-10 and
intensity of exposure to M. tuberculosis have been detected
acutely, although no studies have followed this relationship
through the passage of time (41, 42). However, another study
has suggested an inverse correlation between presumed bacterial
load and magnitude of T-cell response to ESAT-6 and CFP-10 in
patients not on treatment (43). Furthermore, no correlation has
been seen between magnitude of IFN-g response to ESAT-6 and
CFP-10 and radiological disease in patients with active TB or
LTBI (44–47).
Because effective antibiotic regimens cure active TB disease
and antibiotic chemoprophylaxis reduces the likelihood of indi-
viduals developing disease, it seems reasonable to assume that
both are associated with a reduction in numbers of viable bacilli
(48, 49). A significant decline in ESAT-6 responses has been
detected in individuals with active disease on antibiotic treatment
(42, 43, 50–52). In subjects with LTBI after point source exposure,
those given antibiotic chemoprophylaxis demonstrated a signifi-
cant decrease in responses to ESAT-6 and CFP-10 at 18 months
but not at 6 months, contrasting with the insignificant change in
overall frequency of ESAT-6– and CFP-10–specific T cells in the
untreated adults (53). However, there is no evidence for a decline
in ESAT-6 and CFP-10 results at 3 and 6 months after chemo-
prophylaxis in subjects exposed over longer periods (54, 55).
Given the lack of clarity as to the relationship between T cell
response to ESAT-6 and CFP-10 and bacterial load, and the
small number of subjects in this trial, the efficacy of MVA85A
in LTBI cannot be evaluated in this study. Further larger and
randomized trials are now needed to address this question.
This study is limited by the heterogeneity of the population
used and the small sample size. Subjects within this trial were of
varying ages, ethnicities, and countries of birth, with varying
smoking histories. Although the majority had no clear history of
recent M. tuberculosis exposure, it is likely that the interval
betweenM. tuberculosis infection and enrollment in the study was
highly variable. In addition, it is likely that each subject had
different bacterial burdens of M. tuberculosis and it remains
possible that some subjects may have already cleared their
infection at the time of vaccination. Consequently, it would have
been extremely challenging to have obtained a matched control
arm for the study. Some of the heterogeneity could have been
minimized by undertaking this study in a highly endemic country.
However, such a study is likely to have been confounded to
a greater extent by ongoing exposure and infection with M.
tuberculosis. It was also believed to be important to undertake
this first study of MVA85A in subjects with LTBI in the de-
Figure 6. MVA85A vaccination has no effect on early-secreted anti-
genic target (ESAT)-6– and culture filtrate protein (CFP)-10–specific
IFN-g–secreting T cells. Median IFN-g ELISpot responses to summed
peptide pools of antigens (A) ESAT-6, and (B) CFP-10 for n 5 12 for all
time points except Week 4, where n 5 11 due to subject unavailability.
The responses to each antigen at 1 week, 24 weeks, and 52 weeks after
vaccination were compared with week 0 using the Mann-Whitney test.
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veloped world with the back-up of comprehensive health care
facilities. It will be important to investigate safety of MVA85A in
subjects who are contacts of individuals with smear-positive
pulmonary TB by initially administering the vaccine together
with chemoprophylaxis and subsequently comparing the vaccine
alone with chemoprophylaxis alone. We recognize that the safety
of MVA85A will continue to be monitored in subsequent studies
of MVA85A in subjects with LTBI, although using less intensive
methodology compared with this study.
This is the first subunit TB vaccine to enter clinical trials in M.
tuberculosis–infected subjects since Robert Koch experimented
with his ‘‘remedy’’ of culture filtrate protein in 1890 with
devastating consequence (16). We have demonstrated that
MVA85A is safe in healthy subjects who are latently infected
with M. tuberculosis, by close clinical, immunological, and
radiological monitoring. Furthermore, we have demonstrated
that MVA85A is as immunogenic when administered to subjects
infected with M. tuberculosis, as it is when administered to
uninfected individuals who have been primed with BCG. This
trial has enabled further phase II trials of this vaccine to proceed
in an area of high TB endemicity, such as the Western Cape in
South Africa. Subsequent trials with MVA85A will continue to
monitor safety, but will not require the intensive follow-up
performed in this United Kingdom–based phase I trial.
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